Inclusion Criteria:

- Diagnosis of adenocarcinoma of the prostate.

- Failure of local treatments (surgery and/or radiation) as defined by a rising PSA;
demonstrated by at least three consecutive rises in PSA by intervals of at least 4
weeks apart with an absolute change of at least 1 ng/mL. If the confirmatory PSA
(third PSA) is less than the previous screening PSA value, an additional test for
rising PSA will be required to document progression.

- No clinical or radiographic evidence of disease.

- The Zubrod performance status 0-1.

- Prior hormonal therapy in the form of neoadjuvant or adjuvant therapy is allowed as
long as androgen therapy has been completed at least 1 year prior to study entry.

- Adequate hematologic function: absolute granulocytes ≥ 1500/ul, platelets ≥
100,000/ul, hemoglobin ≥ 10 gm/100 ml within 4 weeks prior to study entry.

- Adequate hepatic function: bilirubin ≤ 1.5 mg/dl, liver enzymes ≤ 1.5 ULN within 4
weeks prior to study entry.

- Adequate renal function: creatinine ≤ 1.5 x ULN within 4 weeks prior to study entry.

- Patients treated with bisphosphonate therapy before or after study entry are eligible
to continue in the study.

- Negative bone scan within 6 weeks prior to study entry.

- Negative CT scan or MRI of the abdomen and pelvis within 6 weeks prior to study
entry.

- Negative chest x-ray for metastatic disease within 6 weeks prior to study entry.

- Patients must sign a written informed consent prior to treatment.

Exclusion Criteria:

- Serious intercurrent medical illness including symptomatic heart disease within 6
months.

- Previous or concurrent invasive cancers other than superficial non-melanomatous skin
cancer unless disease-free for at least 5 years.

- Major medical or psychiatric illness which, in the investigator's opinion, would
prevent completion of treatment and would interfere with follow-up.

- History of thromboembolic events (deep venous thrombosis, symptomatic cerebrovascular
events or pulmonary embolism), history of MI, within the last 12 months.

- History of bleeding disorders that would contraindicate Coumadin® (warfarin)
including: esophageal varices and clotting factor defects